ALZFORUM13d
Lecanemab Bested Three Other Antibodies at Binding Soluble Aβ Aggregates
Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...
Hosted on MSN1mon
Alzheimer's Decline May Be Slowed by Protein Boost
One of the major components of these protein buildups was thought to be a protein called amyloid beta, or Aβ42, which clump together into what is known as amyloid plaques. However, a new study ...
ALZFORUM7y
Alzheimer's Disease vs Control: Aβ42 (Plasma and Serum)
However, while the level of Aβ42 in blood is not by itself a good biomarker for AD, the Aβ42:Aβ40 ratio has gained attention as a plasma biomarker that predicts amyloid-PET status regardless of ...
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in ...
Promising Phase II Trial Results Support Buy Rating for Coya Therapeutics’ Alzheimer’s Treatment
Chardan Capital analyst Keay Nakae reiterated a Buy rating on Coya Therapeutics, Inc. (COYA – Research Report) today and set a price ...
New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer’s Disease Diagnostic Information
Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker ...